Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIVE A: Clopidogrel + Aspirin in AF
NCT00249873Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2003
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Clopidogrel + ASA with Placebo + ASA (2 arms). Primary endpoint: First Occurence of Any Component of the Composite of Stroke, Non-Central Nervous System (Non-CNS) Systemic Embolism, Myocardial Infarction or Vascular Death at 3 years. Started Jun 2003; status: completed.
02
Drugs
clopidogrel
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT00249873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249873.